Quest Diagnostics Incorporated DGX
Set alert
250.21 USD -0.60 -0.24%
As of Nov 3, 9:32 AM ET
252.64 Day range 252.64
171.18 52-week range 256.99
- YTD
- +44.19%
- 1 year
- +39.91%
- Open
- 251.60
- Prev close
- 250.81
- Mkt cap
- 27.88B
- Vol
- 17.87K
- Avg vol
- 995.15K
- EPS
- 10.04
- P/E
- 25.16
- Div yield
- 1.36%
More statistics
- Low
- 252.64
- High
- 252.64
- Forward P/E
- 20.94
- Beta
- 0.55
- Short ratio
- 3.05
- Inst. own
- 98.91%
- Dividend
- 3.44
- Ex-div date
- Oct 5, 2026
- Earnings
- Feb 9, 2027
- 50-d avg
- 238.54
- 200-d avg
- 212.15
- 1y target
- 257.27
Analyst view
Consensus: buy
Buy
Price target (mean) 257.27 +2.8% upside
Now 250.21
- Target (low)
- 235.00
- Target (mean)
- 257.27
- Target (high)
- 279.00
Ratings (0m) 17 9 buy · 8 hold · 0 sell
- Strong buy2
- Buy7
- Hold8
- Sell0
- Strong sell0
Recommendation trend
- This month 17
- 1 month ago 17
- 2 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.68 | 2.63 – 2.74 | 2.42 | +10.8% | 3.05B | +8.6% | 13 |
| Next quarter | 2.70 | 2.59 – 2.84 | 2.50 | +7.9% | 3.03B | +4.6% | 10 |
| Current year | 11.32 | 11.25 – 11.43 | 9.85 | +14.9% | 12.08B | +9.5% | 15 |
| Next year | 11.98 | 11.63 – 12.67 | 11.32 | +5.8% | 12.62B | +4.4% | 16 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 21, 2026 | Truist Securities | Maintained | Hold | Hold |
| Sep 8, 2026 | UBS | Maintained | Neutral | Neutral |
| Jul 28, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Jul 24, 2026 | UBS | Maintained | Neutral | Neutral |
| Jul 24, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jul 24, 2026 | Truist Securities | Maintained | Hold | Hold |
| Jul 24, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 24, 2026 | Baird | Maintained | Neutral | Neutral |
| Jul 13, 2026 | Baird | Maintained | Neutral | Neutral |
| Apr 22, 2026 | UBS | Maintained | Neutral | Neutral |
| Apr 22, 2026 | Baird | Maintained | Neutral | Neutral |
| Apr 22, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 22, 2026 | Truist Securities | Maintained | Hold | Hold |
| Apr 8, 2026 | Evercore ISI Group | Maintained | In-Line | In-Line |
| Feb 12, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Feb 11, 2026 | Truist Securities | Maintained | Hold | Hold |
| Feb 11, 2026 | UBS | Maintained | Neutral | Neutral |
| Feb 11, 2026 | Evercore ISI Group | Maintained | In-Line | In-Line |
| Feb 11, 2026 | Barclays | Maintained | Overweight | Overweight |
| Feb 11, 2026 | Jefferies | Maintained | Buy | Buy |
| Feb 10, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Oct 27, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Oct 22, 2025 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Oct 22, 2025 | Truist Securities | Maintained | Hold | Hold |
| Oct 21, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| Oct 21, 2025 | Jefferies | Maintained | Buy | Buy |
| Oct 17, 2025 | UBS | Maintained | Neutral | Neutral |
| Oct 17, 2025 | Mizuho | Maintained | Outperform | Outperform |
| Oct 8, 2025 | Evercore ISI Group | Maintained | In-Line | In-Line |